David J Nutt, Lawrence D Phillips, Michael P Barnes, Brigitta Brander, Helen Valerie Curran, Alan Fayaz, David P Finn, Tina Horsted, Julie Moltke, Chloe Sakal, Haggai Sharon, Saoirse E O'Sullivan, Tim Williams, Gregor Zorn, Anne K Schlag
Background: Pharmacological management of chronic neuropathic pain (CNP) still represents a major clinical challenge. Collective harnessing of both the scientific evidence base and clinical experience (of clinicians and patients) can play a key role in informing treatment pathways and contribute to the debate on specific treatments (e.g., cannabinoids). A group of expert clinicians (pain specialists and psychiatrists), scientists, and patient representatives convened to assess the relative benefit-safety balance of 12 pharmacological treatments, including orally administered cannabinoids/cannabis-based medicinal products, for the treatment of CNP in adults...
August 2022: Cannabis and Cannabinoid Research